MAX-40279 hemifumarate

• CAT Number: I045075
• CAS Number: 2388506-43-0
• Molecular Formula: C22H23FN6OS.1/2C4H4O4
• Molecular Weight: 554.59
• Purity: ≥95%
• IUPAC Name: (E)-but-2-enedioic acid;7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-(1-piperidin-4-ylpyrazol-4-yl)thieno[3,2-d]pyrimidin-2-amine
• InChI: InChI=1S/2C22H23FN6OS.C4H4O4/c2*1-13-20(17-4-3-14(23)9-18(17)30-2)21-19(31-13)11-25-22(28-21)27-15-10-26-29(12-15)16-5-7-24-8-6-16;5-3(6)1-2-4(7)8/h2*3-4,9-12,16,24H,5-8H2,1-2H3,(H,25,27,28);1-2H,(H,5,6)(H,7,8)/b;;2-1+
• InChIKey: BCHMKHOVSSCBHQ-WXXKFALUSA-N
• SMILES: CC1=C(C2=NC(=NC=C2S1)NC3=CN(N=C3)C4CCNCC4)C5=C(C=C(C=C5)F)OC.CC1=C(C2=NC(=NC=C2S1)NC3=CN(N=C3)C4CCNCC4)C5=C(C=C(C=C5)F)OC.C(=C/C(=O)O)\C(=O)O

MAX-40279 hemifumarate（Cat No.:I045075）is an orally active, selective androgen receptor (AR) antagonist with potential use in prostate cancer therapy. It binds competitively to the AR, effectively blocking androgen-induced signaling without displaying significant agonist activity. MAX-40279 is structurally distinct from traditional antiandrogens like enzalutamide, offering efficacy against AR overexpression and resistance mutations such as F876L. Its hemifumarate salt form enhances bioavailability and stability. Preclinical studies support its favorable pharmacokinetics, antitumor activity, and safety profile, making it a promising candidate for castration-resistant prostate cancer (CRPC) treatment development.